PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Are you Meeting Safety Standards for Residual Host Cell DNA?

Are you meeting safety standards for residual host cell DNA?

To realise the incredible potential of cell and gene therapies, scientists must overcome many challenges specific to creating these products. One persistent challenge is residual host cell DNA contamination.

HEK293 cells are a dominant platform for cell and gene therapy production. However, if traces of these host cells are not removed before the final treatment is administered, there can be dangerous immune responses or oncogenic effects.

To ensure patient safety when it comes to host cell DNA contamination, the Food and Drug Administration (FDA) published industry guidance for cell and gene therapy manufacturing:

“Limit the amount of residual DNA for continuous non-tumorigenic cells to less than 10ng/dose and the DNA size to below approximately 200 base pairs. If you are using cells that … have tumorigenic phenotypes (e.g., HEK293, HEK293T), the limitation of specific residual DNA quantities may be needed to assure product safety.”

To ensure adherence to these rigorous guidelines, biopharmaceutical manufacturers need cutting-edge solutions. The traditional method for quantifying residual host cell DNA is quantitative PCR (qPCR), which relies on a standard curve and presents other limitations such as nonspecific signals and lack of reproducibility. In addition, BioAnalyzer technology, widely used for DNA sizing, fails to deliver cell line-specific results and is unable to analyze fragments larger than 7 kilobases.

In contrast, Droplet Digital™ PCR technology (ddPCR™) delivers the high-quality data you need to meet FDA standards. ddPCR technology provides an absolute count of target DNA copies per input sample without relying on standard curves. This capability makes the technique simpler, more precise, and highly sensitive.

The Vericheck ddPCR HEK293 Residual DNA Detection Kits are the first digital PCR HEK293-specific kits, providing an elegant solution that enables absolute quantification and accurate sizing of residual HEK293 DNA on the same instrument. In addition, the kits offer an extraction-free workflow—minimising hands-on time and sample manipulation—and reproducible, quantitative readouts for precise measurement of residual HEK293 DNA.

With these easy-to-use ddPCR assays, you can confirm that the precise amount of residual HEK293 DNA in your cell and gene products falls within the FDA guidelines for every batch. Then, empowered with the knowledge that your products are clear of dangerous contaminants, you can have greater confidence in your work.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40